277 related articles for article (PubMed ID: 23169338)
1. Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
Nitzsche B; Gloesenkamp C; Schrader M; Hoffmann B; Zengerling F; Balabanov S; Honecker F; Höpfner M
Br J Cancer; 2012 Nov; 107(11):1853-63. PubMed ID: 23169338
[TBL] [Abstract][Full Text] [Related]
2. Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours.
Nitzsche B; Gloesenkamp C; Schrader M; Ocker M; Preissner R; Lein M; Zakrzewicz A; Hoffmann B; Höpfner M
Br J Cancer; 2010 Jun; 103(1):18-28. PubMed ID: 20551952
[TBL] [Abstract][Full Text] [Related]
3. Animacroxam, a Novel Dual-Mode Compound Targeting Histone Deacetylases and Cytoskeletal Integrity of Testicular Germ Cell Cancer Cells.
Steinemann G; Dittmer A; Kuzyniak W; Hoffmann B; Schrader M; Schobert R; Biersack B; Nitzsche B; Höpfner M
Mol Cancer Ther; 2017 Nov; 16(11):2364-2374. PubMed ID: 28838999
[TBL] [Abstract][Full Text] [Related]
4. IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.
Selfe J; Goddard NC; McIntyre A; Taylor KR; Renshaw J; Popov SD; Thway K; Summersgill B; Huddart RA; Gilbert DC; Shipley JM
J Pathol; 2018 Feb; 244(2):242-253. PubMed ID: 29160922
[TBL] [Abstract][Full Text] [Related]
5. Activity of nintedanib in germ cell tumors.
Steinemann G; Jacobsen C; Gerwing M; Hauschild J; von Amsberg G; Höpfner M; Nitzsche B; Honecker F
Anticancer Drugs; 2016 Feb; 27(2):89-98. PubMed ID: 26479145
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
7. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine.
Albany C; Hever-Jardine MP; von Herrmann KM; Yim CY; Tam J; Warzecha JM; Shin L; Bock SE; Curran BS; Chaudhry AS; Kim F; Sandusky GE; Taverna P; Freemantle SJ; Christensen BC; Einhorn LH; Spinella MJ
Oncotarget; 2017 Jan; 8(2):2949-2959. PubMed ID: 27936464
[TBL] [Abstract][Full Text] [Related]
8. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model.
Jørgensen A; Blomberg Jensen M; Nielsen JE; Juul A; Rajpert-De Meyts E
J Steroid Biochem Mol Biol; 2013 Jul; 136():238-46. PubMed ID: 23098692
[TBL] [Abstract][Full Text] [Related]
9. Influence of Nodal signalling on pluripotency factor expression, tumour cell proliferation and cisplatin-sensitivity in testicular germ cell tumours.
Harpelunde Poulsen K; Nielsen JE; Grønkær Toft B; Joensen UN; Rasmussen LJ; Blomberg Jensen M; Mitchell RT; Juul A; Rajpert-De Meyts E; Jørgensen A
BMC Cancer; 2020 Apr; 20(1):349. PubMed ID: 32326899
[TBL] [Abstract][Full Text] [Related]
10. Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours.
Rudolph C; Melau C; Nielsen JE; Vile Jensen K; Liu D; Pena-Diaz J; Rajpert-De Meyts E; Rasmussen LJ; Jørgensen A
Cell Oncol (Dordr); 2017 Aug; 40(4):341-355. PubMed ID: 28536927
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity.
Schaffrath J; Schmoll HJ; Voigt W; Müller LP; Müller-Tidow C; Mueller T
PLoS One; 2017; 12(6):e0178930. PubMed ID: 28591197
[TBL] [Abstract][Full Text] [Related]
12. Re: Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
Richie JP
J Urol; 2013 Nov; 190(5):1767-8. PubMed ID: 24120784
[No Abstract] [Full Text] [Related]
13. Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance.
Mueller T; Mueller LP; Luetzkendorf J; Voigt W; Simon H; Schmoll HJ
Tumour Biol; 2006; 27(2):71-83. PubMed ID: 16557044
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy.
Singh R; Fazal Z; Bikorimana E; Boyd RI; Yerby C; Tomlin M; Baldwin H; Shokry D; Corbet AK; Shahid K; Hattab A; Freemantle SJ; Spinella MJ
Mol Oncol; 2022 Feb; 16(3):683-698. PubMed ID: 34482638
[TBL] [Abstract][Full Text] [Related]
15. Genome-scale CRISPR screen reveals neddylation to contribute to cisplatin resistance of testicular germ cell tumours.
Funke K; Einsfelder U; Hansen A; Arévalo L; Schneider S; Nettersheim D; Stein V; Schorle H
Br J Cancer; 2023 Jun; 128(12):2270-2282. PubMed ID: 37024667
[TBL] [Abstract][Full Text] [Related]
16. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
Cavallo F; Graziani G; Antinozzi C; Feldman DR; Houldsworth J; Bosl GJ; Chaganti RS; Moynahan ME; Jasin M; Barchi M
PLoS One; 2012; 7(12):e51563. PubMed ID: 23251575
[TBL] [Abstract][Full Text] [Related]
17. Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer.
Steinemann G; Dittmer A; Schmidt J; Josuttis D; Fähling M; Biersack B; Beindorff N; Jolante Koziolek E; Schobert R; Brenner W; Müller T; Nitzsche B; Höpfner M
Mol Oncol; 2019 Dec; 13(12):2679-2696. PubMed ID: 31583820
[TBL] [Abstract][Full Text] [Related]
18. Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells.
Fung MK; Cheung HW; Ling MT; Cheung AL; Wong YC; Wang X
Br J Cancer; 2006 Aug; 95(4):475-84. PubMed ID: 16880791
[TBL] [Abstract][Full Text] [Related]
19. Differential methylation EPIC analysis discloses cisplatin-resistance related hypermethylation and tumor-specific heterogeneity within matched primary and metastatic testicular germ cell tumor patient tissue samples.
Lobo J; Constâncio V; Leite-Silva P; Guimarães R; Cantante M; Braga I; Maurício J; Looijenga LHJ; Henrique R; Jerónimo C
Clin Epigenetics; 2021 Apr; 13(1):70. PubMed ID: 33823933
[TBL] [Abstract][Full Text] [Related]
20. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]